|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
PrEP HBV Triple Screen Panel with Reflexes
Test Code13660
CPT Codes
87340, 86704, 86317
Includes
PrEP Interpretation
PrEP Hepatitis B Surface Antigen with Reflex Confirm
PrEP Hepatitis B Core Antibody, Total with Reflex IgM
PrEP Hepatitis B Surface Antibody, Quantitative
If Hepatitis B Surface Antigen is Low Positive, then confirmation will be performed at an additional charge (CPT code(s): 87341).
If Hepatitis B Core Antibody, Total is Reactive, then Hepatitis B Core IgM Antibody will be performed at an additional charge (CPT code(s): 86705).
PrEP Hepatitis B Surface Antigen with Reflex Confirm
PrEP Hepatitis B Core Antibody, Total with Reflex IgM
PrEP Hepatitis B Surface Antibody, Quantitative
If Hepatitis B Surface Antigen is Low Positive, then confirmation will be performed at an additional charge (CPT code(s): 87341).
If Hepatitis B Core Antibody, Total is Reactive, then Hepatitis B Core IgM Antibody will be performed at an additional charge (CPT code(s): 86705).
Preferred Specimen
4 mL serum
Minimum Volume
3 mL
Other Acceptable Specimens
Plasma collected in: EDTA (lavender-top) tube
Instructions
Dietary supplements containing biotin may interfere in assays and may skew analyte results to be either falsely high or falsely low. For patients receiving the recommended daily doses of biotin, draw samples at least 8 hours following the last biotin supplementation. For patients on mega-doses of biotin supplements, draw samples at least 72 hours following the last biotin supplementation.
Transport Container
Transport tube
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 5 days
Refrigerated: 14 days
Frozen: 21 days
Refrigerated: 14 days
Frozen: 21 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Grossly lipemic
Methodology
Immunoassay (IA)
Setup Schedule
Set up: Mon-Sat; Report available: 1-2 days
Reference Range
| PrEP Hepatitis B Surface Ag | Non-Reactive |
| PrEP Hepatitis B Surface Ag Confirm | Non-Reactive |
| PrEP Hepatitis B Core Ab, Total | Non-Reactive |
| PrEP Hepatitis B Core Ab (IgM) | Non-Reactive |
| PrEP Hepatitis B Surface Ab, QN | ≥10 mIU/mL |
Clinical Significance
This panel consists of the three tests recommended by the Centers for Disease Control and Prevention for screening for hepatitis B infection: 1) hepatitis B surface antigen (HBsAg); 2) antibody to hepatitis B surface antigen (anti-HBs); 3) total antibody to hepatitis B core antigen (anti-HBc). Low positive HBsAg samples will be confirmed by a HBsAg neutralization test. Reactive total anti-HBc samples will reflex to an anti-HBc IgM test.
This panel can be ordered for universal HBV screening in all adults, including pregnant persons and patients who are at increased risk of acquiring HBV. Current guidelines recommend that asymptomatic adults be screened at least once for HBV. Periodic, repeat testing using this panel can be performed for individuals with appropriate risk factors.
Reference:
Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. MMWR Recomm Rep. 023;72:1-25.
This assay may be performed as part of an overall screening regimen for patients considering or who are currently taking HIV PrEP. Please refer to the "Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2021 Update Clinical Practice Guideline" for additional information.
This panel can be ordered for universal HBV screening in all adults, including pregnant persons and patients who are at increased risk of acquiring HBV. Current guidelines recommend that asymptomatic adults be screened at least once for HBV. Periodic, repeat testing using this panel can be performed for individuals with appropriate risk factors.
Reference:
Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. MMWR Recomm Rep. 023;72:1-25.
This assay may be performed as part of an overall screening regimen for patients considering or who are currently taking HIV PrEP. Please refer to the "Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2021 Update Clinical Practice Guideline" for additional information.
